<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00036790</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000069322</org_study_id>
    <secondary_id>P30CA014520</secondary_id>
    <secondary_id>WCCC-CO-01910</secondary_id>
    <secondary_id>PCI-PCYC-0207</secondary_id>
    <secondary_id>NCI-G02-2061</secondary_id>
    <nct_id>NCT00036790</nct_id>
  </id_info>
  <brief_title>Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced Cancer</brief_title>
  <official_title>An Open-Label Phase I Dose Escalation Trial To Evaluate The Safety And Pharmacokinetics Of Motexafin Gadolinium And Doxorubicin Chemotherapy In The Treatment Of Advanced Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Wisconsin, Madison</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Wisconsin, Madison</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
      they stop growing or die. Motexafin gadolinium may increase the effectiveness of doxorubicin
      by making tumor cells more sensitive to the drug.

      PURPOSE: Phase I trial to study the effectiveness of combining motexafin gadolinium with
      doxorubicin in treating patients who have recurrent or metastatic cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Determine the maximum tolerated dose of motexafin gadolinium and doxorubicin in patients
           with advanced malignancies.

        -  Determine the dose-limiting toxicity of this regimen in these patients.

        -  Determine the safety and tolerability of this regimen in these patients.

        -  Determine the pharmacokinetics of this regimen in these patients.

        -  Evaluate the tumor response in patients treated with this regimen.

      OUTLINE: This is a dose-escalation, multicenter study. Patients are assigned to 1 of 2
      groups.

      Group A:

        -  Course 1: Patients receive motexafin gadolinium IV over 30 minutes on days 1, 8, 9, and
           10 and doxorubicin IV over 15 minutes on day 8.

        -  Course 2: 28 days after the beginning of course 1, patients receive doxorubicin IV over
           15 minutes.

        -  Courses 3-6: Beginning 21 days after course 2, patients receive doxorubicin IV over 15
           minutes on day 1 and motexafin gadolinium IV over 30 minutes on days 1-3. Treatment
           repeats every 21 days.

      Group B:

        -  Course 1: Patients receive motexafin gadolinium IV over 30 minutes on day 1 and
           doxorubicin IV over 15 minutes on day 8.

        -  Course 2: 28 days after the beginning of course 1, patients receive doxorubicin IV over
           15 minutes on day 1 and motexafin gadolinium IV over 30 minutes on days 1-3.

        -  Courses 3-6: Beginning 21 days after course 2, patients receive doxorubicin and
           motexafin gadolinium as in group A.

      Treatment in both groups continues for up to 6 courses in the absence of disease progression,
      unacceptable toxicity, or a cumulative doxorubicin dose of 450 mg/m^2.

      Cohorts of 3-6 patients receive escalating doses of doxorubicin and motexafin gadolinium
      until the maximum tolerated dose (MTD) is determined. The MTD is defined as the highest dose
      at which no more than 0 of 3 or 1 of 6 patients experience dose-limiting toxicity.

      Patients are followed at 1 and 2 months.

      PROJECTED ACCRUAL: A total of 3-48 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2002</start_date>
  <primary_completion_date type="Actual">October 2005</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Breast Cancer</condition>
  <condition>Chronic Myeloproliferative Disorders</condition>
  <condition>Colorectal Cancer</condition>
  <condition>Head and Neck Cancer</condition>
  <condition>Leukemia</condition>
  <condition>Lung Cancer</condition>
  <condition>Lymphoma</condition>
  <condition>Multiple Myeloma and Plasma Cell Neoplasm</condition>
  <condition>Myelodysplastic/Myeloproliferative Diseases</condition>
  <condition>Prostate Cancer</condition>
  <condition>Small Intestine Cancer</condition>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>motexafin gadolinium</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically confirmed advanced malignancy that is considered incurable

               -  Recurrent or metastatic disease

               -  Relapsed solid tumors include, but are not limited to the following sites:

                    -  Lung

                    -  Breast

                    -  Colon

                    -  Prostate

                    -  Head and neck

          -  Hormone receptor status:

               -  Not specified

        PATIENT CHARACTERISTICS:

        Age:

          -  18 and over

        Sex

          -  Not specified

        Menopausal status

          -  Not specified

        Performance status:

          -  ECOG 0-2

        Life expectancy:

          -  Not specified

        Hematopoietic:

          -  Absolute neutrophil count at least 1,500/mm^3

          -  Platelet count at least 100,000/mm^3

        Hepatic:

          -  Bilirubin no greater than 1.5 mg/dL

          -  AST and ALT no greater than 2 times upper limit of normal

        Renal:

          -  Creatinine no greater than 2.0 mg/dL

        Cardiovascular:

          -  LVEF greater than 45% at rest

          -  No prior myocardial infarction

          -  No congestive heart failure

          -  No clinically significant ventricular arrhythmias

        Other:

          -  No history of HIV infection

          -  No history of porphyria

          -  No glucose-6-phosphate dehydrogenase deficiency

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception during and for at least 6 months
             after study participation

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  Not specified

        Chemotherapy:

          -  At least 28 days since prior chemotherapy

          -  No prior lifetime cumulative doxorubicin exposure of more than 300 mg/m^2

          -  No other concurrent cytotoxic chemotherapy

        Endocrine therapy:

          -  Not specified

        Radiotherapy:

          -  At least 28 days since prior radiotherapy

          -  No concurrent radiotherapy

        Surgery:

          -  No concurrent surgery

        Other:

          -  At least 14 days since prior multidrug resistance-modulating drugs (e.g., PSC833 or
             cyclosporine)

          -  No other concurrent antineoplastic or investigational agents
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Markus Renschler, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Pharmacyclics LLC.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hillman Cancer Center at University of Pittsburgh Cancer Institute</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin Comprehensive Cancer Center</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 13, 2002</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>September 30, 2015</last_update_submitted>
  <last_update_submitted_qc>September 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 2, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage III adult Hodgkin lymphoma</keyword>
  <keyword>stage IV adult Hodgkin lymphoma</keyword>
  <keyword>recurrent adult Hodgkin lymphoma</keyword>
  <keyword>stage III cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>stage IV cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>isolated plasmacytoma of bone</keyword>
  <keyword>extramedullary plasmacytoma</keyword>
  <keyword>refractory multiple myeloma</keyword>
  <keyword>Waldenstrom macroglobulinemia</keyword>
  <keyword>stage III multiple myeloma</keyword>
  <keyword>stage III chronic lymphocytic leukemia</keyword>
  <keyword>stage IV chronic lymphocytic leukemia</keyword>
  <keyword>recurrent adult acute myeloid leukemia</keyword>
  <keyword>recurrent adult acute lymphoblastic leukemia</keyword>
  <keyword>relapsing chronic myelogenous leukemia</keyword>
  <keyword>refractory chronic lymphocytic leukemia</keyword>
  <keyword>small intestine lymphoma</keyword>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <keyword>chronic phase chronic myelogenous leukemia</keyword>
  <keyword>accelerated phase chronic myelogenous leukemia</keyword>
  <keyword>blastic phase chronic myelogenous leukemia</keyword>
  <keyword>meningeal chronic myelogenous leukemia</keyword>
  <keyword>untreated adult acute lymphoblastic leukemia</keyword>
  <keyword>untreated adult acute myeloid leukemia</keyword>
  <keyword>refractory hairy cell leukemia</keyword>
  <keyword>chronic myelomonocytic leukemia</keyword>
  <keyword>T-cell large granular lymphocyte leukemia</keyword>
  <keyword>acute undifferentiated leukemia</keyword>
  <keyword>stage III grade 1 follicular lymphoma</keyword>
  <keyword>stage III grade 2 follicular lymphoma</keyword>
  <keyword>stage III grade 3 follicular lymphoma</keyword>
  <keyword>stage III adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>stage III adult diffuse mixed cell lymphoma</keyword>
  <keyword>stage III adult diffuse large cell lymphoma</keyword>
  <keyword>stage III adult immunoblastic large cell lymphoma</keyword>
  <keyword>stage III adult lymphoblastic lymphoma</keyword>
  <keyword>stage III adult Burkitt lymphoma</keyword>
  <keyword>stage IV grade 1 follicular lymphoma</keyword>
  <keyword>stage IV grade 2 follicular lymphoma</keyword>
  <keyword>stage IV grade 3 follicular lymphoma</keyword>
  <keyword>stage IV adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
  <keyword>stage IV adult diffuse large cell lymphoma</keyword>
  <keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
  <keyword>stage IV adult lymphoblastic lymphoma</keyword>
  <keyword>stage IV adult Burkitt lymphoma</keyword>
  <keyword>recurrent grade 1 follicular lymphoma</keyword>
  <keyword>recurrent grade 2 follicular lymphoma</keyword>
  <keyword>recurrent grade 3 follicular lymphoma</keyword>
  <keyword>recurrent adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
  <keyword>recurrent adult diffuse large cell lymphoma</keyword>
  <keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
  <keyword>recurrent adult lymphoblastic lymphoma</keyword>
  <keyword>recurrent adult Burkitt lymphoma</keyword>
  <keyword>stage III adult T-cell leukemia/lymphoma</keyword>
  <keyword>stage IV adult T-cell leukemia/lymphoma</keyword>
  <keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
  <keyword>secondary acute myeloid leukemia</keyword>
  <keyword>prolymphocytic leukemia</keyword>
  <keyword>stage III mantle cell lymphoma</keyword>
  <keyword>stage IV mantle cell lymphoma</keyword>
  <keyword>recurrent mantle cell lymphoma</keyword>
  <keyword>angioimmunoblastic T-cell lymphoma</keyword>
  <keyword>anaplastic large cell lymphoma</keyword>
  <keyword>stage III mycosis fungoides/Sezary syndrome</keyword>
  <keyword>stage IV mycosis fungoides/Sezary syndrome</keyword>
  <keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
  <keyword>chronic eosinophilic leukemia</keyword>
  <keyword>chronic neutrophilic leukemia</keyword>
  <keyword>recurrent non-small cell lung cancer</keyword>
  <keyword>recurrent small cell lung cancer</keyword>
  <keyword>stage IIIA non-small cell lung cancer</keyword>
  <keyword>stage IIIB non-small cell lung cancer</keyword>
  <keyword>stage IV non-small cell lung cancer</keyword>
  <keyword>extensive stage small cell lung cancer</keyword>
  <keyword>limited stage small cell lung cancer</keyword>
  <keyword>recurrent breast cancer</keyword>
  <keyword>stage IIIA breast cancer</keyword>
  <keyword>stage IIIB breast cancer</keyword>
  <keyword>stage IIIC breast cancer</keyword>
  <keyword>stage IV breast cancer</keyword>
  <keyword>recurrent colon cancer</keyword>
  <keyword>stage III colon cancer</keyword>
  <keyword>stage IV colon cancer</keyword>
  <keyword>recurrent prostate cancer</keyword>
  <keyword>stage III prostate cancer</keyword>
  <keyword>stage IV prostate cancer</keyword>
  <keyword>recurrent lip and oral cavity cancer</keyword>
  <keyword>stage III lip and oral cavity cancer</keyword>
  <keyword>stage IV lip and oral cavity cancer</keyword>
  <keyword>recurrent paranasal sinus and nasal cavity cancer</keyword>
  <keyword>stage III paranasal sinus and nasal cavity cancer</keyword>
  <keyword>stage IV paranasal sinus and nasal cavity cancer</keyword>
  <keyword>recurrent metastatic squamous neck cancer with occult primary</keyword>
  <keyword>recurrent hypopharyngeal cancer</keyword>
  <keyword>stage III hypopharyngeal cancer</keyword>
  <keyword>stage IV hypopharyngeal cancer</keyword>
  <keyword>recurrent laryngeal cancer</keyword>
  <keyword>stage III laryngeal cancer</keyword>
  <keyword>stage IV laryngeal cancer</keyword>
  <keyword>recurrent oropharyngeal cancer</keyword>
  <keyword>stage III oropharyngeal cancer</keyword>
  <keyword>stage IV oropharyngeal cancer</keyword>
  <keyword>recurrent nasopharyngeal cancer</keyword>
  <keyword>stage III nasopharyngeal cancer</keyword>
  <keyword>stage IV nasopharyngeal cancer</keyword>
  <keyword>atypical chronic myeloid leukemia</keyword>
  <keyword>myelodysplastic/myeloproliferative disease, unclassifiable</keyword>
  <keyword>recurrent marginal zone lymphoma</keyword>
  <keyword>recurrent small lymphocytic lymphoma</keyword>
  <keyword>stage III small lymphocytic lymphoma</keyword>
  <keyword>stage III marginal zone lymphoma</keyword>
  <keyword>stage IV small lymphocytic lymphoma</keyword>
  <keyword>stage IV marginal zone lymphoma</keyword>
  <keyword>extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue</keyword>
  <keyword>nodal marginal zone B-cell lymphoma</keyword>
  <keyword>splenic marginal zone lymphoma</keyword>
  <keyword>adult acute myeloid leukemia with t(8;21)(q22;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(16;16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with inv(16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with 11q23 (MLL) abnormalities</keyword>
  <keyword>adult acute myeloid leukemia with t(15;17)(q22;q12)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Plasmacytoma</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
    <mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
    <mesh_term>Intestinal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Motexafin gadolinium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

